Dabigatran - Metabolism, Pharmacologic Properties and Drug Interactions

被引:46
作者
Antonijevic, Nebojsa M. [1 ,2 ]
Zivkovic, Ivana D. [1 ]
Jovanovic, Ljubica M. [1 ]
Matic, Dragan M. [1 ,2 ]
Kocica, Mladen J. [3 ]
Mrdovic, Igor B. [1 ,2 ]
Kanjuh, Vladimir I. [4 ]
Culafic, Milica D. [5 ]
机构
[1] Clin Ctr Serbia, Clin Cardiol, Belgrade, Serbia
[2] Univ Belgrade, Sch Med, Belgrade, Serbia
[3] Clin Ctr Serbia, Clin Cardiosurg, Belgrade, Serbia
[4] Serbian Acad Arts & Sci, Board Cardiovasc Pathol, Belgrade, Serbia
[5] Univ Belgrade, Dept Pharmacokinet & Clin Pharm, Fac Pharm, Belgrade, Serbia
关键词
Dabigatran; pharmacokinetics; pharmacodynamics; dose optimization; interactions; metabolism; comorbidities; ORAL DIRECT THROMBIN; TOTAL HIP-REPLACEMENT; VENOUS THROMBOEMBOLISM; INHIBITOR DABIGATRAN; ATRIAL-FIBRILLATION; RANDOMIZED EVALUATION; ISCHEMIC-STROKE; CONCOMITANT USE; P-GLYCOPROTEIN; RENAL-FUNCTION;
D O I
10.2174/1389200218666170427113504
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Background: The superiority of dabigatran has been well proven in the standard dosing regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and extended venous thromboembolism (VTE) treatment. Dabigatran, an anticoagulant with a good safety profile, reduces intracranial bleeding in patients with atrial fibrillation and decreases major and clinically relevant non-major bleeding in acute VTE treatment. However, several important clinical issues are not fully covered by currently available directions with regard to dabigatran administration. The prominent one is reflected in the fact that dynamic impairment in renal function due to dehydratation may lead to haemorragic complications on the one hand, while on the other hand glomerular hyperfiltration may be a possible cause of dabigatran subdosing, hence reducing the drug's efficacy. Furthermore, limitations of the Cockcroft-Gault formula, considered a standard equation for assessing the renal function, may imply that other calculations are likely to obtain more accurate estimates of the kidney function in specific patient populations. Method and Conclusions: Although not routinely recommended, a possibility of monitoring dabigatran in special clinical settings adds to optimization of its dosage regimens, timely perioperative care and administration of urgently demanded thrombolytic therapy, therefore significantly improving this drug's safety profile. Despite the fact that dabigatran has fewer reported interactions with drugs, food constituents, and dietary supplements, certain interactions still remain, requiring considerable caution, notably in elderly, high bleeding risk patients, patients with decreased renal function and those on complex drug regimens. Additionally, upon approval of idarucizumab, an antidote to dabigatran solution, hitherto being a major safety concern, has been finally reached, which plays a vital role in life-threatening bleeding and emergency interventions and surgery.
引用
收藏
页码:622 / 635
页数:14
相关论文
共 84 条
[1]
Herbal medicines and perioperative care [J].
Ang-Lee, MK ;
Moss, J ;
Yuan, CS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (02) :208-216
[2]
Contribution of Novel Anticoagulants Fondaparinux and Dabigatran to Venous Thromboembolism Prevention [J].
Antonijevic, Nebojsa ;
Kanjuh, Vladimir ;
Zivkovic, Ivana ;
Jovanovic, Ljubica ;
Vukcevic, Miodrag ;
Apostolovic, Milan .
SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2015, 143 (3-4) :230-236
[3]
The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes [J].
Becker, Richard C. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 41 (02) :273-278
[4]
The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans [J].
Blech, Stefan ;
Ebner, Thomas ;
Ludwig-Schwellinger, Eva ;
Stangier, Joachim ;
Roth, Willy .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (02) :386-399
[5]
Idarucizumab: First Global Approval [J].
Burness, Celeste B. .
DRUGS, 2015, 75 (18) :2155-2161
[6]
Dosing of dabigatran etexilate in relation to renal function and drug interactions at a tertiary hospital [J].
Chin, P. K. L. ;
Vella-Brincat, J. W. A. ;
Walker, S. L. ;
Barclay, M. L. ;
Begg, E. J. .
INTERNAL MEDICINE JOURNAL, 2013, 43 (07) :778-783
[7]
Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].
Connolly, Stuart J. ;
Ezekowitz, Michael D. ;
Yusuf, Salim ;
Eikelboom, John ;
Oldgren, Jonas ;
Parekh, Amit ;
Pogue, Janice ;
Reilly, Paul A. ;
Themeles, Ellison ;
Varrone, Jeanne ;
Wang, Susan ;
Alings, Marco ;
Xavier, Denis ;
Zhu, Jun ;
Diaz, Rafael ;
Lewis, Basil S. ;
Darius, Harald ;
Diener, Hans-Christoph ;
Joyner, Campbell D. ;
Wallentin, Lars .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151
[8]
Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication [J].
Cuker, Adam .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 41 (02) :241-247
[9]
Cupp MJ, 1999, AM FAM PHYSICIAN, V59, P1239
[10]
Dabigatran Etexilate, DABIGATRAN ETEXILATE